Published in Virol J on March 15, 2010
Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol (2013) 1.51
Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog (2011) 1.22
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One (2011) 1.10
The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect (2010) 1.03
Inhibition of apoptosis and NF-κB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog (2011) 1.00
Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc Natl Acad Sci U S A (2013) 0.97
Myxoma virus and the Leporipoxviruses: an evolutionary paradigm. Viruses (2015) 0.96
Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa. PLoS Pathog (2011) 0.96
Genetic screen of a mutant poxvirus library identifies an ankyrin repeat protein involved in blocking induction of avian type I interferon. J Virol (2013) 0.94
Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One (2013) 0.92
Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol (2013) 0.90
The current status and future directions of myxoma virus, a master in immune evasion. Vet Res (2011) 0.90
Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol (2013) 0.86
Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J Gen Virol (2013) 0.86
Deerpox virus encodes an inhibitor of apoptosis that regulates Bak and Bax. J Virol (2010) 0.86
The vaccinia virus-encoded Bcl-2 homologues do not act as direct Bax inhibitors. J Virol (2011) 0.84
Vaccinia virus protein A49 is an unexpected member of the B-cell Lymphoma (Bcl)-2 protein family. J Biol Chem (2015) 0.83
Orthopoxvirus genes that mediate disease virulence and host tropism. Adv Virol (2012) 0.83
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol (2014) 0.83
Characterization and structure of the vaccinia virus NF-κB antagonist A46. J Biol Chem (2013) 0.82
Genetic screen of a library of chimeric poxviruses identifies an ankyrin repeat protein involved in resistance to the avian type I interferon response. J Virol (2013) 0.80
The vaccinia virus K7 protein promotes histone methylation associated with heterochromatin formation. PLoS One (2017) 0.77
Viral infection: an evolving insight into the signal transduction pathways responsible for the innate immune response. Adv Virol (2012) 0.77
Structural Conservation and Functional Diversity of the Poxvirus Immune Evasion (PIE) Domain Superfamily. Viruses (2015) 0.77
Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens. J Virol (2013) 0.76
Vaccinia virus virulence factor N1 can be ubiquitylated on multiple lysine residues. J Gen Virol (2014) 0.76
Vaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2. PLoS Pathog (2016) 0.75
Basic local alignment search tool. J Mol Biol (1990) 659.07
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics (2003) 130.85
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol (2003) 102.57
MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics (2001) 101.31
Profile hidden Markov models. Bioinformatics (1998) 56.04
Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol (1999) 33.07
The Pfam protein families database. Nucleic Acids Res (2007) 30.53
Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform (2008) 22.07
Protein homology detection by HMM-HMM comparison. Bioinformatics (2004) 21.92
The Universal Protein Resource (UniProt) 2009. Nucleic Acids Res (2008) 14.82
3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics (2003) 7.99
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature (2000) 4.36
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology (1998) 4.13
Distinct molecular mechanism for initiating TRAF6 signalling. Nature (2002) 3.82
A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A (2000) 3.69
NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38
Phylemon: a suite of web tools for molecular evolution, phylogenetics and phylogenomics. Nucleic Acids Res (2007) 3.09
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B (1978) 2.92
The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med (2003) 2.85
Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J Virol (2003) 2.70
Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med (2005) 2.66
Pathogen recognition in the innate immune response. Biochem J (2009) 2.64
Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J (2008) 2.53
Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A (2008) 2.43
Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol (2006) 2.38
Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem (2004) 2.21
Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ (2008) 1.80
Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol (2007) 1.73
IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J Biol Chem (2007) 1.68
The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67
Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog (2008) 1.63
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 1.57
Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog (2008) 1.57
The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol (2002) 1.57
Streamlining and large ancestral genomes in Archaea inferred with a phylogenetic birth-and-death model. Mol Biol Evol (2009) 1.54
Poxvirus immunomodulatory strategies: current perspectives. J Virol (2003) 1.52
Poxvirus Bioinformatics Resource Center: a comprehensive Poxviridae informational and analytical resource. Nucleic Acids Res (2005) 1.47
A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. Mol Cell (2007) 1.47
Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci (2006) 1.45
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35
Poxvirus genome evolution by gene gain and loss. Mol Phylogenet Evol (2005) 1.34
Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol (2008) 1.22
Identification of multiple independent horizontal gene transfers into poxviruses using a comparative genomics approach. BMC Evol Biol (2008) 1.18
Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J Biol Chem (2005) 1.16
Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol (2006) 1.14
Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci (2007) 1.11
Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings. J Proteome Res (2009) 1.07
Genome of crocodilepox virus. J Virol (2006) 1.06
Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7. Structure (2009) 1.01
Fowlpox virus encodes a Bcl-2 homologue that protects cells from apoptotic death through interaction with the proapoptotic protein Bak. J Virol (2007) 0.96
Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation. J Immunol (2005) 0.90
A single nucleotide substitution in the 5'-untranslated region of the vaccinia N2L gene is responsible for both alpha-amanitin-resistant and temperature-sensitive phenotypes. Virology (1991) 0.85
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24
Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol (2003) 1.97
Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol (2002) 1.94
Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev (2006) 1.94
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68
The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67
Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol (2004) 1.65
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 1.57
Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog (2008) 1.57
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55
ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog (2013) 1.51
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43
TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol (2004) 1.40
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35
Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol (2006) 1.26
Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol (2002) 1.26
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine (2008) 1.25
MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther (2011) 1.24
Human cytomegalovirus final envelopment on membranes containing both trans-Golgi network and endosomal markers. Cell Microbiol (2009) 1.23
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One (2010) 1.20
Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol (2005) 1.19
Resistance to viral infection of super p53 mice. Oncogene (2005) 1.17
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene (2002) 1.15
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15
Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS (2010) 1.14
The ESCRT machinery is not required for human cytomegalovirus envelopment. Cell Microbiol (2007) 1.13
Vaccinia virus induces apoptosis of infected macrophages. J Gen Virol (2002) 1.12
Cryo-X-ray tomography of vaccinia virus membranes and inner compartments. J Struct Biol (2009) 1.11
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One (2011) 1.10
A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine (2002) 1.06
Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol (2007) 1.06
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol (2011) 1.06
Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04
IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol (2003) 1.04
The impact of PKR activation: from neurodegeneration to cancer. FASEB J (2014) 1.04
Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol (2004) 1.02
Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol (2007) 1.02
Antiviral action of the tumor suppressor ARF. EMBO J (2006) 1.02
Evidence that avian reovirus sigmaA protein is an inhibitor of the double-stranded RNA-dependent protein kinase. J Gen Virol (2003) 1.01
Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun (2005) 1.01
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01
Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol (2009) 1.01
Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis (2015) 1.00
Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00
Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol (2003) 1.00
F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS One (2009) 0.99
Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J Biol Chem (2006) 0.98
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A (2008) 0.98
Cryo X-ray nano-tomography of vaccinia virus infected cells. J Struct Biol (2011) 0.98
Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol (2012) 0.98
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol (2011) 0.97
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol (2014) 0.97
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96
Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines (2013) 0.95
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One (2011) 0.92
Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One (2013) 0.92
Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol (2010) 0.92
Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine (2004) 0.92
Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant. Virol J (2005) 0.91
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol (2010) 0.91
A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS One (2011) 0.91
Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89
Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine (2010) 0.89
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One (2012) 0.87
A vaccinia virus lacking A10L: viral core proteins accumulate on structures derived from the endoplasmic reticulum. Cell Microbiol (2006) 0.86
Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res (2005) 0.86
MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect (2006) 0.86
Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J Virol (2011) 0.85
High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One (2012) 0.85
Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Lett (2002) 0.85
Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother (2014) 0.85
The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One (2011) 0.84
Control of virus infection by tumour suppressors. Carcinogenesis (2007) 0.84
Activation of NF-kB pathway by virus infection requires Rb expression. PLoS One (2009) 0.84
Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections. J Virol (2007) 0.83
Membrane remodelling during vaccinia virus morphogenesis. Biol Cell (2009) 0.83
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol (2014) 0.83
Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis. J Virol (2005) 0.83
Host-range restriction of vaccinia virus E3L deletion mutant can be overcome in vitro, but not in vivo, by expression of the influenza virus NS1 protein. PLoS One (2011) 0.82
Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection. Vaccine (2005) 0.82
New vaccinia virus promoter as a potential candidate for future vaccines. J Gen Virol (2013) 0.80
Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence. PLoS One (2011) 0.80
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One (2012) 0.80
Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein. J Immunol (2012) 0.79
Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector. Virol J (2008) 0.79
Identification of cellular genes induced in human cells after activation of the OAS/RNaseL pathway by vaccinia virus recombinants expressing these antiviral enzymes. J Interferon Cytokine Res (2010) 0.78